Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing
AstraZeneca's Adoption of CTScreen v1.5: AstraZeneca has adopted Medera Inc.'s advanced automated cardiac screening platform, CTScreen v1.5, which utilizes bioengineered human heart tissues for efficient drug development and aims to reduce reliance on animal testing.
Innovations in Cardiac Screening Technology: The upgraded CTScreen system features enhanced automation, improved physiological conditions, and a high-throughput 96-well format, allowing rapid screening of miniature human heart tissues, thus accelerating the path from discovery to clinical trials.
Trade with 70% Backtested Accuracy
Analyst Views on KVACW
No data
About the author
Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome
Mini-Heart Models Development: A collaboration between Medera, Novoheart, and leading medical institutions aims to create the first human mini-heart models from stem cells of hypoplastic left heart syndrome (HLHS) patients, enhancing understanding and treatment personalization for this severe congenital heart condition.
Focus on Personalized Treatment: The initiative seeks to improve survival rates and quality of life for pediatric HLHS patients by identifying which individuals may benefit most from various treatments, leveraging advanced 3D bioengineered cardiac tissues that better replicate human heart function compared to traditional models.
Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025
Presentation Highlights: Medera Inc. showcased seven presentations at the ISSCR 2025, including a significant oral presentation on their first-in-human gene therapy for heart failure, utilizing their innovative human mini-Heart technology, which supports clinical trials and regulatory approvals.
Regulatory Advances: The FDA has recognized Medera's human-based screening platform as an animal-free alternative in drug development, emphasizing its potential to enhance drug classification, patient-specific disease modeling, and accelerate clinical translation while aligning with new federal policies.
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
Medera Inc. Clinical Trial Announcement: Medera Inc. will present data from its MUSIC-HFpEF clinical trial on the gene therapy candidate SRD-002 for heart failure with preserved ejection fraction (HFpEF) at the Heart Failure 2025 Congress in Belgrade, Serbia, highlighting the need for new therapeutic interventions in this area.
Company Background and Merger Plans: Medera, a biopharmaceutical company focused on developing next-generation therapeutics, is in the process of merging with Keen Vision Acquisition Corporation (KVAC), aiming to enhance its capabilities in targeting difficult-to-treat diseases.
Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht
Cutting-Edge Cardiac Research: Novoheart's CTScreen™ system has been installed at UMC Utrecht, enhancing capabilities for human cardiac disease modeling and therapeutic screening, which will facilitate advancements in drug development and gene editing approaches.
Driving Innovation: This collaboration between Novoheart and UMC Utrecht is expected to lead to breakthroughs in cardiovascular research and strengthen their partnership in exploring innovative cardiac regenerative technologies.
Medera, Inc. to Participate in Two Upcoming Investor Conferences
Medera's Upcoming Investor Conferences: Medera, a clinical-stage biotechnology company, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11 and will also be available for meetings at the BIO CEO & Investor Conference on February 10 and 11.
Merger Agreement with Keen Vision Acquisition Corp: Medera has entered into a definitive merger agreement with Keen Vision Acquisition Corp, focusing on developing next-generation therapies for difficult-to-treat diseases, leveraging their innovative mini-Heart technology for drug discovery and validation.
Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening
Innovative Partnership: Medera's Novoheart has partnered with Curi Bio to integrate their human "Heart-in-a-Jar" technology with Curi Bio’s Pulse™ analytics, enhancing cardiac drug screening and aligning with the FDA Modernization Act 2.0 for ethical preclinical models.
Accelerated Drug Development: The collaboration aims to significantly improve efficiency in drug development processes, reducing time and costs while increasing predictivity, ultimately leading to safer and more effective therapies for patients.
Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome
Mini-Heart Models Development: A collaboration between Medera, Novoheart, and leading medical institutions aims to create the first human mini-heart models from stem cells of hypoplastic left heart syndrome (HLHS) patients, enhancing understanding and treatment personalization for this severe congenital heart condition.
Focus on Personalized Treatment: The initiative seeks to improve survival rates and quality of life for pediatric HLHS patients by identifying which individuals may benefit most from various treatments, leveraging advanced 3D bioengineered cardiac tissues that better replicate human heart function compared to traditional models.
Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025
Presentation Highlights: Medera Inc. showcased seven presentations at the ISSCR 2025, including a significant oral presentation on their first-in-human gene therapy for heart failure, utilizing their innovative human mini-Heart technology, which supports clinical trials and regulatory approvals.
Regulatory Advances: The FDA has recognized Medera's human-based screening platform as an animal-free alternative in drug development, emphasizing its potential to enhance drug classification, patient-specific disease modeling, and accelerate clinical translation while aligning with new federal policies.
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
Medera Inc. Clinical Trial Announcement: Medera Inc. will present data from its MUSIC-HFpEF clinical trial on the gene therapy candidate SRD-002 for heart failure with preserved ejection fraction (HFpEF) at the Heart Failure 2025 Congress in Belgrade, Serbia, highlighting the need for new therapeutic interventions in this area.
Company Background and Merger Plans: Medera, a biopharmaceutical company focused on developing next-generation therapeutics, is in the process of merging with Keen Vision Acquisition Corporation (KVAC), aiming to enhance its capabilities in targeting difficult-to-treat diseases.
Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht
Cutting-Edge Cardiac Research: Novoheart's CTScreen™ system has been installed at UMC Utrecht, enhancing capabilities for human cardiac disease modeling and therapeutic screening, which will facilitate advancements in drug development and gene editing approaches.
Driving Innovation: This collaboration between Novoheart and UMC Utrecht is expected to lead to breakthroughs in cardiovascular research and strengthen their partnership in exploring innovative cardiac regenerative technologies.
Medera, Inc. to Participate in Two Upcoming Investor Conferences
Medera's Upcoming Investor Conferences: Medera, a clinical-stage biotechnology company, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11 and will also be available for meetings at the BIO CEO & Investor Conference on February 10 and 11.
Merger Agreement with Keen Vision Acquisition Corp: Medera has entered into a definitive merger agreement with Keen Vision Acquisition Corp, focusing on developing next-generation therapies for difficult-to-treat diseases, leveraging their innovative mini-Heart technology for drug discovery and validation.
Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening
Innovative Partnership: Medera's Novoheart has partnered with Curi Bio to integrate their human "Heart-in-a-Jar" technology with Curi Bio’s Pulse™ analytics, enhancing cardiac drug screening and aligning with the FDA Modernization Act 2.0 for ethical preclinical models.
Accelerated Drug Development: The collaboration aims to significantly improve efficiency in drug development processes, reducing time and costs while increasing predictivity, ultimately leading to safer and more effective therapies for patients.
